Jim SkaggsChairman of the Board & CEO
Jim has been with Aminex since 2012. He was one of six top executives with NASA’s Apollo lunar landing program management, and he has spent almost 40 years in several corporate leadership positions in high-tech electronics systems, heavy infrastructure maintenance equipment manufacturing, and biotech drug development. Jim is retired chairman of Alamo Group, Inc. (NYSE) Prior to that, as chairman, CEO, and president of Tracor Inc., he led the turnaround and six times growth of Tracor in the defense electronics industry with 10,000 employees. Tracor was a Fortune 100 Fastest Growing Company. Jim graduated with a bachelor’s degree in mechanical engineering from the University of Washington and has received numerous honorary awards.
Mark Burns, PhDPresident & Chief Scientific Officer, Director
Dr. Burns is the scientific founder of Aminex. Mark earned a PhD at the University of Michigan and post-doctoral training in bio-organic chemistry at Rice University. During his over 20 years of experience in biotechnology Mark led the discovery efforts resulting in Aminex’s AMXT 1501/DFMO assets. Mark has obtained 15 U.S. Patents and published 21 scientific papers. He has extensive experience in the fields of medicinal, combinatorial, enzyme inhibitor design, analytical and process chemistry.
Tom GrahamChief Operating Officer, Director
Tom Graham has served as a director or CEO of several companies, including three in the life sciences and drug discovery fields. In executive roles at Oridigm and MediQuest Therapeutics he authorized the early AMXT 1501/DFMO research program and worked directly on it with Dr. Mark Burns. He rejoined Mark at Aminex in 2011 and led its early funding and restructuring, including combining with his long time friend and business associate Jim Skaggs. Tom’s extensive business, entrepreneurial, and consulting experience spans multiple industries with both large and small companies. He received both his bachelor’s degree in mechanical engineering and MBA from the University of Washington.
Michael G. Palfreyman, PhD, DSc, MRPharmSSenior Vice President of Drug Development & Chairman Scientific Advisory Board
Dr. Michael Palfreyman has more than four decades of successful drug discovery and development experience with two major pharmaceutical companies and several biotechnology companies. He is currently chief scientific officer at Amorsa Therapeutics, a director of Oculogics, and scientific advisor to Jasco Pharmaceuticals, and he is responsible for research and development diligence at Torrey Pines Investment Ventures. Previously he was chairman of Amakem Therapeutics and Opthakem, vice president of drug development and program management at EnVivo (now Forum) Pharmaceuticals, and senior vice president of research and development at Scriptgen (now Anadys) Pharmaceuticals. Michael also held executive positions at Marion Merrell Dow (MMD) Research Institute (now Sanofi), including vice president of research (North America), and was a key member of the team that developed DFMO (eflornithine). Prior to MMD, Michael was the head of biochemical pharmacology at Beecham Pharmaceuticals (now GlaxoSmithKline). He received his BPharm, MRPharmS, PhD, and DSc from the University of Nottingham. He is co-inventor on 45 US and European patents and three pending patents, and has coauthored over 150 scientific articles and book chapters.
Kathy Fosnaugh, PhDProject Manager, Preclinical Science
Dr. Kathy Fosnaugh has 25 years of experience in biotech research and development. Most recently she was Director of Research at Youtell Biochemical. Prior to this, as Associate Director of Discovery Research and Pharmaceutical Development at Marina Therapeutics (formerly Nastech Pharmaceuticals), Dr. Fosnaugh was instrumental in nucleic acid therapeutics and delivery programs in cancer, autoimmune, and metabolic disease areas. Previously she held scientist positions at Sirna Therapeutics and Ligand Pharmaceuticals. She has published 13 scientific articles and co-authored 17 patents. Kathy received her BS and PhD degrees in microbiology from the University of Illinois and Cornell University, respectively, followed by postdoctoral research in developmental biology at the University of California, San Diego.
Nicole GallegosConsultant, Director of Clinical Operations
Nicole Gallegos, is responsible for directing Clinical Trial operations for Aminex. She has over 17 years of industry experience in both Clinical Operations and Clinical Data Management working for multiple pharmaceutical, biotechnology, medical device, and contract research organizations, including management and leadership of global teams. Nicole is an experienced program manager with strong knowledge of clinical operations, data management, regulatory data requirements, clinical trial process, biostatistics, quality management, and systems applications. She graduated from Belmont University in Nashville, TN with an MBA and concentration in Health Care Management. Prior to graduate work she received a Bachelors of Science in Biology with a pre-medicine focus from the University of Texas San Antonio.
Greg Coulter, PhDConsultant, CMC/Product Development
Greg is currently President of CTM Solutions, LLC, a CMC and clinical trial materials consultancy. He has over 20 years’ experience in GLP, GMP and GCP regulated drug product development, and is a subject matter expert in drug substance synthesis, scale up, process development, and analytical characterization. He also provides regulatory CMC guidance. Greg completed his PhD in Biological Chemistry, at the University of Guelph, Ontario, Canada and postdoctoral training at University of Denver. He has held positions of increasing responsibility at Synthetech, Cell Therapeutics, and SNBL USA. Most recently Dr. Coulter has worked on development teams leading to the FDA approval of the weight loss drug Contrave and the PI3K delta inhibitor Zydelig.